| Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial CC Parker, NW Clarke, AD Cook, HG Kynaston, PM Petersen, C Catton, ... The Lancet 396 (10260), 1413-1421, 2020 | 299 | 2020 |
| Active surveillance for clinically localized prostate cancer––A systematic review FB Thomsen, K Brasso, LH Klotz, MA Røder, KD Berg, P Iversen Journal of surgical oncology 109 (8), 830-835, 2014 | 248 | 2014 |
| Validation of the self‐administered Danish Prostatic Symptom Score (DAN‐PSS‐1) system for use in benign prostatic hyperplasia BJ Hansen, H Flyger, K Brasso, J Schou, J Nordling, JT Andersen, ... British journal of urology 76 (4), 451-458, 1995 | 189 | 1995 |
| Socioeconomic position and participation in colorectal cancer screening BL Frederiksen, T Jørgensen, K Brasso, I Holten, M Osler British journal of cancer 103 (10), 1496-1501, 2010 | 151 | 2010 |
| Prognostic value of PINP, bone alkaline phosphatase, CTX‐I, and YKL‐40 in patients with metastatic prostate carcinoma K Brasso, IJ Christensen, JS Johansen, B Teisner, P Garnero, PA Price, ... The Prostate 66 (5), 503-513, 2006 | 141 | 2006 |
| Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis K Brasso, FB Thomsen, AJ Schrader, SC Schmid, D Lorente, M Retz, ... European urology 68 (2), 317-324, 2015 | 134 | 2015 |
| Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis B Malling, MA Røder, K Brasso, J Forman, M Taudorf, L Lönn European radiology 29, 287-298, 2019 | 131 | 2019 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 127 | 2022 |
| Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy J Uth, T Hornstrup, JF Schmidt, JF Christensen, C Frandsen, ... Scandinavian journal of medicine & science in sports 24, 105-112, 2014 | 120 | 2014 |
| First-in-human uPAR PET: imaging of cancer aggressiveness M Persson, D Skovgaard, M Brandt-Larsen, C Christensen, J Madsen, ... Theranostics 5 (12), 1303, 2015 | 109 | 2015 |
| ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer KD Berg, B Vainer, FB Thomsen, MA Røder, TA Gerds, BG Toft, K Brasso, ... European urology 66 (5), 851-860, 2014 | 108 | 2014 |
| Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study T Steuber, KD Berg, MA Røder, K Brasso, P Iversen, H Huland, A Tiebel, ... European urology focus 3 (6), 646-649, 2017 | 100 | 2017 |
| Determinants of participation in colorectal cancer screening with faecal occult blood testing M von Euler-Chelpin, K Brasso, E Lynge Journal of public health 32 (3), 395-405, 2010 | 92 | 2010 |
| Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow … J Uth, T Hornstrup, JF Christensen, KB Christensen, NR Jørgensen, ... Osteoporosis International 27, 1507-1518, 2016 | 88 | 2016 |
| Postdiagnosis statin use and mortality in Danish patients with prostate cancer SB Larsen, C Dehlendorff, C Skriver, SO Dalton, CG Jespersen, M Borre, ... Journal of Clinical Oncology 35 (29), 3290-3297, 2017 | 80 | 2017 |
| Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—A population‐based analysis of 2 national cohorts JT Helgstrand, MA Røder, N Klemann, BG Toft, DY Lichtensztajn, ... Cancer 124 (14), 2931-2938, 2018 | 74 | 2018 |
| Short-term morbidity and mortality following radical cystectomy: a systematic review SL Maibom, UN Joensen, AM Poulsen, H Kehlet, K Brasso, MA Røder BMJ open 11 (4), e043266, 2021 | 73 | 2021 |
| Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate FB Thomsen, MA Røder, P Rathenborg, K Brasso, M Borre, P Iversen Scandinavian journal of urology 48 (3), 268-275, 2014 | 73 | 2014 |
| Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival JS Johansen, K Brasso, P Iversen, B Teisner, P Garnero, PA Price, ... Clinical cancer research 13 (11), 3244-3249, 2007 | 73 | 2007 |
| Safety, dosimetry, and tumor detection ability of 68Ga-NOTA-AE105: first-in-human study of a novel radioligand for uPAR PET imaging D Skovgaard, M Persson, M Brandt-Larsen, C Christensen, J Madsen, ... Journal of Nuclear Medicine 58 (3), 379-386, 2017 | 71 | 2017 |
Andreas RøderCopenhagen Prostate Cancer Center在 regionh.dk 的电子邮件经过验证
